CASE REPORT
Acute liver failure due to previously unrecognised dilated cardiomyopathy in a 17-year-old boy with Duchenne muscular dystrophy
1
Department of Gastroenterology, Hepatology, Nutritional Disorders, and Paediatrics, The Children’s Memorial Health Institute, Warsaw, Poland
2
Department of Cardiology, The Children’s Memorial Health Institute, Warsaw, Poland
3
Department of Anaesthesiology, The Children’s Memorial Health Institute, Warsaw, Poland
4
Department of Paediatric Surgery and Organ Transplantation, The Children’s Memorial Health Institute, Warsaw, Poland
5
Department of Nephrology, The Children’s Memorial Health Institute, Warsaw, Poland
Submission date: 2020-04-02
Final revision date: 2020-06-07
Acceptance date: 2020-06-08
Publication date: 2020-10-30
Pediatr Pol 2020;95(3):178-183
KEYWORDS
TOPICS
ABSTRACT
We present a case of fatal liver failure secondary to previously unrecognised dilated cardiomyopathy in a 17-year-old boy with Duchenne muscular dystrophy (DMD). Acute liver failure in the clinical course of decompensated dilated cardiomyopathy in patients with DMD is rare and carries a high mortality rate. Severe congestive heart failure should always be considered as a possible cause of acute liver failure. In our article we summarise current recommendations including diagnostic and therapeutic standards regarding cardiac care in patients with DMD. Regular cardiac evaluation according to recommendations may detect the early stage of dilated cardiomyopathy and allow the implementation of preventive pharmacological treatment. Multispecialist management increases the survival and provides a better quality of life for children with DMD.
REFERENCES (26)
1.
Correale M, Tarantino N, Petrucci R, et al. Liver disease and heart failure: Back and forth. Eur J Intern Med 2018; 48: 25-34.
2.
Scarpati G, De Robertis E, Esposito C, Piazza O. Hepatic encephalopathy and cirrhotic cardiomyopathy in Intensive Care Unit. Minerva Anestesiol 2018; 84: 970-979.
3.
Saner FH, Heuer M, Meyer M, et al. When the heart kills the liver: acute liver failure in congestive heart failure. Eur J Med Res 2009; 14: 541-546.
4.
Fussell KM, Awad JA, Ware LB. Case of fulminant hepatic failure due to unrecognized peripartum cardiomyopathy. Crit Care Med 2005; 33: 891-893.
5.
Wagle K, Akinseye OA, Shrestha P, et al. A Case of Fulminant Hepatic Failure Secondary to Congestive Heart Failure Without Evidence of Acute Cardiac Decompensation. S D Med 2017; 70: 155-159.
6.
Kaymakcalan H, Dourdourekas D, Szanto PB, Steigmann F. Congestive heart failure as cause of fulminant hepatic failure. Am J Med 1978; 65: 384-388.
7.
Kisloff B, Schaffer G. Fulminant hepatic failure secondary to congestive heart failure. Am J Dig Dis 1976; 21: 895-900.
8.
Wiesen S, Reddy KR, Jeffers LJ, Schiff ER. Fulminant hepatic failure secondary to previously unrecognized cardiomyopathy. Dig Dis 1995; 13: 199-204.
9.
Karasek D, Sinkiewicz W. Problemy kardiologiczne chorych z dystrofiami nerwowo-mięśniowymi. Kardiol Dypl 2012; 11: 32-36.
10.
Schade van Westrum SM, Hoogerwaard EM, Dekker L, et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology 2011; 77: 62-66.
11.
Thrush PT, Allen HD, Viollet L, et al. Re-examination of the electrocardiogram in boys with Duchenne muscular dystrophy and correlation with its dilated cardiomyopathy. Am J Cardiol 2009; 103: 262-265.
12.
Bourke JP, Watson G, Muntoni F, et al. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study. BMJ Open 2018; 8: e022572.
13.
Doing AH, Renlund DG, Smith RA. Becker muscular dystrophy-related cardiomyopathy: A favorable response to medical therapy. J Heart Lung Transplant 2002; 21: 496-498.
14.
Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003; 13: 166-172.
15.
Rhodes J, Margossian R, Darras BT, et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008; 29: 343-351.
16.
Viollet L, Thrush PT, Flanigan KM, et al. Effects of angiotensin converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012; 110: 98-102.
17.
Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006; 70: 991-994.
18.
Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009; 53: 72-78.
19.
Fairclough RJ, Bareja A, Davies KE. Progress in therapy for Duchenne muscular dystrophy. Exp Physiol 2011; 96: 1101-1113.
20.
Sun G, Haginoya K, Dai H, et al. Intramuscular renin-angiotensin system is activated in human muscular dystrophy. J Neurol Sci 2009; 280: 40-48.
21.
McNally EM, Kaltman JR, Benson DW, et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation 2015; 131: 1590-1598.
22.
Kwiatkowska J, Meyer-Szary J, Bazgier M, et al. Left ventricular volumes and function affected by myocardial fibrosis in patients with Duchenne and Becker muscular dystrophies: a preliminary magnetic resonance study. Kardiol Pol 2020; 78: 331-334.
23.
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018; 17: 251-267.
24.
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018; 17: 347-361.
25.
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 2018; 17: 445-455.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
